Category Archives: Diabetes

May 24, 2017

An innovative method for treating type 1 diabetes based on the transplantation of hematopoietic stem cells taken from the patient's own bone marrow began undergoing testing in Brazil 13 years ago. The results were highly variable. While some of the volunteers were able to stop self-injecting insulin for more than a decade, others had to resume use of the medication only a few months after receiving the experimental treatment.

A possible explanation for this discrepancy in the clinical outcome for the 25 patients included in the study was presented in an article published recently in the journal Frontiers in Immunology. According to the authors, the duration of the therapeutic effect was shorter in the patients whose immune systems had attacked the pancreatic cells more aggressively in the pre-transplantation period.

This research was conducted at the Center for Cell-Based Therapy (CTC) in Brazil. Initially led by immunologist Julio Voltarelli, who died in March 2012, it is proceeding under the coordination of researchers Maria Carolina de Oliveira Rodrigues and Belinda Pinto Simes.

"Because type 1 diabetes is an autoimmune disease, the aim of the treatment is to 'switch off' the immune system temporarily using chemotherapy drugs and 'restart' it by means of the transplantation of autologous hematopoietic stem cells, which can differentiate into every kind of blood cell," Rodrigues explained.

By the time the symptoms of type 1 diabetes appear, she added, around 80 percent of the patient's pancreatic islets have already been damaged. If the autoimmune aggression is interrupted at this point, and the remaining cells are protected, the patient can produce an amount of insulin that is small but nevertheless important.

"Studies with animals and diabetic humans suggest the percentage of insulin-producing cells declines sharply, reaching almost zero between six and eight weeks after diagnosis. Our center has therefore set a six-week limit for patients to start the transplantation process," Rodrigues said.

Twenty-five volunteers aged between 12 and 35 were initially included in the study. The therapeutic effect has lasted an average of 42 months (3.5 years) but ranges overall from six months to 12 years, the longest follow-up period so far. Three patients remain completely insulin-free. One has been insulin-free for ten years, another for 11, and the third for 12.

"In this more recent study, we compared the profiles of the volunteers who remained insulin-free for less than and more than 42 months, which was our cutoff point," Rodrigues said.

The variables considered included age, time between diagnosis and transplantation, pre-treatment insulin dose, and post-transplant recovery of defense cells.

"We observed no significant differences between the groups for any of these factors," Rodrigues said. "The only exception was the degree of pancreatic inflammation before the transplant, which did vary significantly."

This discovery was made possible by collaboration with Dutch researcher Bart Roep at the Leiden University Medical Center. Roep's analysis of blood samples taken from all 25 patients before treatment and once per year after the transplant enabled him to quantify their autoreactive T-lymphocytes, white cells that recognize and specifically attack proteins secreted by pancreatic islets.

"This method enabled us to evaluate the extent to which the immune system was attacking the pancreas," Rodrigues said. "We observed a clear association between a larger number of autoreactive lymphocytes before transplantation and a worse response to treatment."

In the group of patients who responded well, Rodrigues went on, stem cell therapy rebalanced the immune system thanks to an increase in the proportion of regulatory T-cells (Tregs), a type of white cell with immunosuppressive action that helps combat autoimmunity.

"In patients with more autoreactive lymphocytes before transplantation, this balance didn't occur," she said. "Despite the increase in the number of Tregs due to the treatment, they were still outnumbered by autoreactive lymphocytes. What we don't yet know is whether these were new cells that differentiated from transplanted stem cells or were a remnant of the autoreactive lymphocytes that weren't destroyed by chemotherapy and resumed multiplication."

Data from the scientific literature show that the latter hypothesis is more plausible, so the group at CTC has begun a second study in which patients are being subjected to more aggressive chemotherapy with the aim of ensuring that no vestiges of autoreactive T-lymphocytes remain.

Explore further: Novel tissue-engineered islet transplant achieves insulin independence in type 1 diabetes

More information: Kelen C. R. Malmegrim et al. Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes, Frontiers in Immunology (2017). DOI: 10.3389/fimmu.2017.00167

Scientists from the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine have produced the first clinical results demonstrating that pancreatic islet cells transplanted within a tissue-engineered ...

Type 1 diabetes is caused by the body's own immune system attacking its pancreatic islet beta cells and requires daily injections of insulin to regulate the patient's blood glucose levels. A new method described in BioMed ...

A team of researchers, led by investigators at the University of Colorado School of Medicine, have identified a new class of antigens that may be a contributing factor to type 1 diabetes, according to an article published ...

A Yale-led research team identified how insulin-producing cells that are typically destroyed in type 1 diabetes can change in order to survive immune attack. The finding may lead to strategies for recovering these cells in ...

Type 1 diabetes (T1D) patients who have developed low blood sugar (hypoglycemia) as a complication of insulin treatments over time are able to regain normal internal recognition of the condition after receiving pancreatic ...

A study carried out in India examining the safety and efficacy of self-donated (autologous), transplanted bone marrow stem cells in patients with type 2 diabetes (TD2M), has found that patients receiving the transplants, ...

Research led by the University of Adelaide is paving the way for safer and more effective drugs to treat type 2 diabetes, reducing side effects and the need for insulin injections.

Type 2 diabetes, a prolific killer, is on a steep ascent. According to the World Health Organization, the incidence of the condition has grown dramatically from 108 million cases in 1980 to well over 400 million today. The ...

A widely used diabetes medication could help people with a common inherited form of autism, research shows.

A potential cure for Type 1 diabetes looms on the horizon in San Antonio, and the novel approach would also allow Type 2 diabetics to stop insulin shots.

Researchers investigating a form of adult-onset diabetes that shares features with the two better-known types of diabetes have discovered genetic influences that may offer clues to more accurate diagnosis and treatment.

Pancreatic beta cells help maintain normal blood glucose levels by producing the hormone insulinthe master regulator of energy (glucose). Impairment and the loss of beta cells interrupts insulin production, leading to ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Original post:
Success of stem cell therapy for diabetes depends on pre-transplant immune condition - Medical Xpress

Patch.com

UT-Austin Researchers Seek to Prevent Diabetes in At-Risk Population Patch.com AUSTIN, TX Researchers at The University of Texas at Austin and The University of Texas Health Science Center at Houston (UTHealth) School of Public Health have received a $2.9 million, five-year award from the National Institute of Diabetes and ...

Here is the original post:
UT-Austin Researchers Seek to Prevent Diabetes in At-Risk Population - Patch.com

Northwest Wyoming now claims one of only two health care professionals in the state who holds a certification in Advanced Diabetes Management. West Park Hospitals Registered Dietitian Nutritionist, Liz Fabrizio, has passed the boards for Advanced Diabetes Management from the American Association of Diabetes Educators. Thats an important resource, considering that the adult diabetes rate has almost doubled in Wyoming in the last 15 years. According to West Park Hospital Public Relations Director Ashley Trudo, Fabrizios certification supports her advanced level of knowledge and ability to manage complex patient needs while assisting patients with therapeutic problem-solving. http://dehayf5mhw1h7.cloudfront.net/wp-content/uploads/sites/761/2017/05/24091827/Trudo-Diabetes-Specialist.mp3 In just 15 years, the adult diabetes rate rose from 4.5 percent in 2001 to 8.4 percent in 2016. Christine Revere, Chronic Disease Prevention Program manager with the Wyoming Department of Health, said the trend is not surprising when considered along with several risk factors linked with type 2 diabetes. 65 percent of Wyoming adults are obese or overweight, 83 percent dont eat enough fruits and vegetables, 25 percent engage in no daily physical activity, and 21 percent smoke cigarettes. Uncontrolled diabetes can result in medical difficulties such as blindness, kidney disease and nerve damage. Diabetes is also an important risk factor for heart disease and stroke.

Here is the original post:
Diabetes Specialist Now at West Park Hospital - mybighornbasin

The possible complications posed by diabetesheart disease and damage to eyes, feet, nerves and so forthare fairly familiar to the general public. But in recent years, scientists have been scrutinizing a risk that is both less well known and less understoodthe heightened likelihood of dementia.

Researchers have known for several years about diabetes and the higher risk of vascular dementia, the second most common kind. In ways, it seems only logical: Vascular dementia is caused by damaged blood vessels in the brain, just as diabetes hardens blood vessels elsewhere.

The latest research is focused on Alzheimers disease, the most common neurodegenerative disorder and one for which its harder to figure out the precise relationship with diabetes. On this much, many scientists agree: The rate of Alzheimers disease could be cut by close to half if diabetes could be abolished. The connection between the two is so strong that Suzanne M. de la Monte, one of the top researchers in the field, has said that many cases of Alzheimers could be dubbed Type 3 diabetes.

People who havent necessarily developed diabetes might still develop insulin resistance in the brain, said de la Monte, a professor of neurosurgery, pathology and laboratory medicine at Brown University. Thats why she uses the term Type 3 diabetesone doesnt necessarily cause the other. But in both cases, she said, people show certain markers at the cellular level.

Growing evidence supports the concept that Alzheimers disease is fundamentally a metabolic disease with molecular and biochemical features that correspond with diabetes mellitus and other peripheral insulin resistance disorders, de la Monte wrote in 2014 in the journal Biochemical Pharmacology.But the picture is more complicated than that, she wrote, because Alzheimers can occur as a separate disease process, or arise in association with systemic insulin resistance diseases, including diabetes, obesity, and non-alcoholic fatty liver disease.

A 2015 pilot study published in the Journal of Alzheimers Disease found that doses of nasal insulinbypassing the blood/brain barriersignificantly improved memory in people with early Alzheimers disease and mild cognitive impairment. A larger, five-year clinical trial is now underway.

Inflammatory response appears to play a role, de la Monte said. Both diabetes and Alzheimers are inflammatory diseases. And yet, other forms of brain inflammation are not associated with cognitive problems later on.

Multiple sclerosis, encephalitis, none of these lead to dementia, she said. What is the cause of all this, where is the problem? Because Alzheimers disease was not that common before. We can link a lot of the extra cases to diabetes and obesity. So if we have that, is it just because people are fatter? I dont think its just that. But then if you talk about metabolic syndrome, fatty liver, PCOS, infertilityhow many diseases are linked to the same problem of insulin resistance and an inflammatory process?

People need a lot more help in learning how to stave off Type 2 diabetes and other metabolic diseases through diet and exercise, de la Monte said. And because testing can find the same precursor conditions for both brain insulin-resistance and diabetes, theres reason to think more people should be screened earlier, with these more sensitive tests.

Melissa Schilling, a professor at the New York University Stern School of Business, came to a similar conclusion after conducting a review of the relationship between diabetes and Alzheimers.

Her 2016 paper in the Journal of Alzheimers Disease estimated that 40% of all Alzheimers cases were connected to hyperinsulinemia, or excess levels of insulin relative to glucose in the blood. That would include not just people with diabetes but the 86 million Americans estimated by the CDC to have prediabetes.

If we can raise awareness and get more people tested for hyperinsulinemia it could significantly lessen the incidence of Alzheimers disease and vascular dementia, as well as other diabetes-related health problems. Schilling said in a press release.

Research by Margaret Gatz, a professor of psychology at USC, further refined the relationship between the two. She and fellow researchers in Sweden found that not only was diabetes strongly associated with dementia, but that people who are first diagnosed with Type 2 diabetes in middle age, rather than after age 65, are at much higher risk. And that finding was independent of how long people had diabetes before developing dementiain other words, it was the age at diagnosis, not how long they lived with diabetes, that determined their risk.

At this point, Gatz is particularly interested in the role that stress might play in the equation.

One theory is Ive been intrigued by involves the HPA (hypothalamic-pituitary-adrenal) axis, she said. The HPA axis controls the immune system, digestionand reactions to stress. Its what fires when someone is stressed, Gatz said. After its heavily activated, it might potentiate diabetes and hippocampal damage, inflammation and oxidative damage.

Maybe this whole stress process is basically inflammatory damage, oxidative damage.

She agreed that earlier, more sensitive testing might warn people away from the kind of eating and sedentary habits that can cause prediabetes and diabetes. Stress management might be part of the picture, too, she suggests.

Im heavily a physical exercise proponent. When people ask me, Whats the biggest thing I can do to avoid dementia? my answer is exercise. But also workplaces are more stressful, people describe themselves as not handling stress as well. All of these are risk factors.

At Brown, de la Monte is planning to publish a paper that looks at what kinds of testing might best be used as early indicators of future dementia. Were looking at peripheral markers that indicate brain disease, she said. If you look at blood, can you find evidence of inflammation in people who have no inflammatory disease but they have mild cognitive impairment and they also have markers of insulin resistance? We can pick out from that who is at risk. At least to inform them so they can start using lifestyle measures.

Karin Klein is a freelance journalist based in Southern California who specializes in writing about health and medicine, education, environment and food. For 27 years, she covered those topics at the Los Angeles Times as an editor and editorial writer. Karin is a graduate of Wellesley College, where she majored in linguistics, and she studied journalism at UC Berkeley's Graduate School of Journalism. When she's not writing, she's usually found on hiking trails and is the author of an interpretive hiking book, "50 Hikes in Orange County." Follow her on Twitter athttps://twitter.com/kklein100

See the rest here:
The Alarming Diabetes-Alzheimer's Connection - A Sweet Life (blog)

Xconomy San Diego

San Diego-based ViaCyte said it is ready to move into human testing with a new product intended for patients with Type 1 diabetes who are at high risk for acute, life-threatening complications from severe episodes of low blood sugar (hypoglycemia).

ViaCyte said Monday that healthcare regulators in both the United States and Canada have permitted the company to proceed with the early stage clinical trial, which calls for enrolling roughly 40 patients at medical centers that include UC San Diego and the University of Alberta in Edmonton, Canada. The goal of the trial is to assess the safety of the PEC-Direct product candidate and provide definitive evidence of efficacy.

According to ViaCyte, demonstrating efficacy with just 40 patients is a function of having a well-defined endpointdefined in this case as a clinically significant production of insulin in a patient population that has no ability to produce insulin when enrolled.

In a separate statement, ViaCyte said it has raised an additional $10 million to initiate the clinical trial and for other corporate purposes. Participants in the financing include the materials science company W.L. Gore & Associates, which is already working with ViaCyte, Asset Management Partners, and other undisclosed investors.

The non-profit research group JDRF also participated in the financing, according to the company.

Since 2004, when three companies merged to form what is now ViaCyte, the company has raised about $100 million from investors, and $75 million in project funding from JDRF and the California Institute for Regenerative Medicine (CIRM).

ViaCyte was founded to advance technology that encapsulates pancreatic progenitor cells (stem cells engineered to develop into fully differentiated pancreatic cells) within a semi-permeable membrane. This packet is implanted under the skin. Once the pancreatic cells develop fully, they secrete insulin and other hormones that pass through the membrane, similar to how tea seeps out of a tea bag. White blood cells are too big to penetrate the membrane, however, so the packet protects the implanted pancreatic cells from a patients own immune system.

In March, ViaCyte said it has been developing a new type of packet called PEC-Direct, for Type 1 diabetes patients who are prone to severe hypoglycemic episodes. The company has engineered this membrane so a patients blood vessels can grow through the membrane and connect directly with the stem cell-derived pancreatic cells. In this case, however, the membrane is not designed to protect against a patients immune system. So PEC-Direct patients would also get immune-suppressant drugs.

Insulin therapy has transformed Type 1 diabetes from a death sentence to a chronic illness, but it is far from a cure, said Paul Laikind, president and CEO of ViaCyte. Patients with Type 1 diabetes must still deal the daily impact of the disease and are at risk for long-term complications.

The company said PEC-Direct is targeting a subset of patients with Type 1 diabetes who are at high risk for life-threatening events because they are acutely vulnerable to severe hypoglycemic episodes, or they cant really tell when or if they are hypoglycemic.

ViaCyte estimates that about 140,000 people in the United States and Canada are at risk for severe hypoglycemic episodes.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788

View original post here:
ViaCyte Raises $10M, Moves to Human Trial with New Diabetes Product - Xconomy

New York Daily News

How to keep sex alive and well when you have diabetes New York Daily News A chronic illness has a way of throwing a wrench into many aspects of our lives, including sex. Type 2 diabetes is one such disease in which sexuality is commonly affected and difficulties experienced by both men and women with this condition. Not only ...

Originally posted here:
How to keep sex alive and well when you have diabetes - New York Daily News

IndyCar driver Conor Daly comes from a competitive family, so when he was diagnosed with Type 1 diabetes at 14, family members took it as another challenge hed beat on the way to a racing career.

Beth Boles, a novice jet ski world title winner in 1990, said of her son: He never thought it was going to prohibit him. Im competitive. Well figure it out.

As one of three known drivers in an IndyCar or NASCAR series with Type 1 diabetes, Daly hopes he can be a positive example to others.

If I can be an inspiration, yeah, that would be awesome, Daly said. I dont know if I am. If they think I am, then cool. Thats great.

Boles remembered her dad, a doctor, saying increased thirst could be a sign of diabetes.

I remember it was Christmas, and he asked for a refrigerator for his room, she said of her son. Im like, Why do you want a refrigerator? That way I can put my drinks in it and stuff. Im like, Thats kind of crazy.

BEHIND THE SCENES: Meet rising race star Conor Daly

ROBBED: Dixon, Franchitti held up at Taco Bell drive-thru

When Daly went to a go-kart race shortly afterward, Boles got a call from Dalys father, former Formula One driver Derek Daly, saying he could hardly get him out of bed.

It was advised to get him to a hospital after calls were made to family friends who were doctors.

We didnt know how it would be responded to, if people would let us race anymore, Daly said of being diagnosed. Kind of just kept doing our thing.

That thing was winning. He won the 2006 World Karting Association Junior Nationals. He won the Skip Barber National Championship with five wins in 2008 and the Star Mazda Championship with a series-record seven wins in 2010.

Boles acknowledged that, like many mothers, she was sensitive early on about whether he took his insulin before go-karting. She became more worried when he went to Europe to race.

I made him wear a dogtag, Boles said.

That identified him as someone with diabetes.

Someone just like Charlie Kimball, a Californian who also had gone to Europe to compete. He missed four races in 2007 while driving in the World Series by Renault after he was diagnosed with Type 1 diabetes. He drove in the F3 Euroseries in 2008, then returned to the USA in 2009 to help promote diabetes awareness when he signed to race in the Indy Lights Series.

BORG-WARNER: Handlers dedicated to trophys protection

MARIO ANDRETTI: Legend says state of IndyCar in good shape

Kimball now drives the No. 83 Tresiba Honda in the Verizon IndyCar Series. When he won at Mid-Ohio Sports Car Course in 2013, he became the first driver with Type 1 diabetes to win in the IndyCar Series.

Kimball, who will start 16th in the 101st running of the Indianapolis 500 on Sunday, has partnered with Novo Nordisk to raise awareness for diabetes.

Like Kimball, Daly races with a glucose monitor that transmits data so hes aware if his glucose level falls during a race.

Daly, who will start 26th on Sunday, wears a Dexcom G5 sensor during the race.

The team cant monitor me, he said. I just have one (monitor) in the car to see, and its connected to my phone as well.

Never been an issue. Never has, and as long as I do my job, then it shouldnt be.

Daly worked with Lilly Diabetes last year but now drives the No. 4 ABC Supply Co. Chevrolet for A.J. Foyt Racing.

Daly, Kimball and NASCAR Xfinity Series driver Ryan Reed are the three known drivers in national racing series with Type 1 diabetes.

Fair credit to him, Daly said of Kimball raising awareness of Type 1 diabetes through sponsorships in racing. I was jealous, for sure. That did a lot of great things for him. For me, I worked a little bit with Lilly Diabetes last year, which was great. But I really have no affiliations with many people in the drug industry at all. I just go about my own business, help where I can in the Juvenile (Diabetes) Research Foundation.

Life just takes a little bit more work, but theres no sense in letting it stop you. It is annoying at times, very annoying. But in the end, its something that can be managed, as long as you do your job.

George Sipple write for the Detroit Free Press, part of the USA TODAY Network.

Here is the original post:
Conor Daly sees diabetes as mere hurdle during IndyCar career ... - USA TODAY

Its not always easy to be a kid with type 1 diabetes, and nobody knows that better thanEric Paslay.

But now that hes a successful country star, the She Dont Love You crooner, 34, wants to help young people who are living with the disease just like him. On Saturday, Paslay headed to Joslin Diabetes Center in Boston to chat with pediatric diabetes patients. In addition to giving a special private performance for the patients, Paslay engaged with the kids as they shared experiences about living with the autoimmune disease. He even compared glucose numbers with a few who had the same Dexcom monitor as him.

One patient asked him what it was like to live with diabetes on the road and Paslayemphasized the importance of always being aware and never being afraid to ask for help when it is needed. He also admitted he keeps a glass of orange juice nearby during all performances, including the one at Joslin, in case his blood sugar starts to dip.

Paslay, who has said hes definitely had scary moments on stage in the past, explained that his wifeNatalie and other members of his team can monitor his blood sugar level remotely while he is performing to watch out for trouble.

He really took the time to get to know our patients and bond with them about his own experiences living with type 1 diabetes, Dr. Peter Amenta, President and CEO of Joslin Diabetes Center, told PEOPLE. It was a very special day for all of us.

Paslay was in Boston to perform at the Massachusetts Fallen Heroes 2nd annual Patriot Fest concert, which he headlined with country singer Tyler Farr at the Lawn on D. While there, the two spent time with MA Gold Star family members and veterans at a private VIP meet and greet. Of course, he did manage to get in some down time: After the concert, he enjoyed clam chowder and crab cakes at Legal Sea Foods.

Follow this link:
Eric Paslay Treats Pediatric Diabetes Patients to a Private Concert and Compares Glucose Monitors! - PEOPLE.com

LONDON AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.

But the British drugmaker's established Bydureon medicine for diabetes failed to show a hoped-for benefit in reducing heart risks, putting it at a disadvantage to Novo Nordisk's rival Victoza in the so-called GLP-1 drug class.

Novo's next-generation GLP-1 drug semaglutide, currently awaiting approval, has also shown such a heart benefit.

The mixed news left AstraZeneca's shares little changed in early dealings on Tuesday.

While most investor focus is on AstraZeneca's cancer research, particularly the immunotherapy drug durvalumab, the company also has a long history in respiratory therapy and a significant presence in diabetes.

It plans to build on the lung expertise with new asthma drug benralizumab, which will compete with GlaxoSmithKline's Nucala and Teva's Cinqair - two other recently approved antibody drugs for severe asthma.

AstraZeneca hopes its product's potency and convenient dosing will give it an edge, despite being third to market.

Data from the 28-week Phase III clinical trial presented at the American Thoracic Society and published in the New England Journal of Medicine on Monday showed the median reduction in oral steroid dose was 75 percent for patients on benralizumab.

Overall, patients treated with benralizumab were more than four times as likely to cut steroid use than those on placebo and there was also a 70 percent reduction in the rate of serious asthma attacks, known as exacerbations.

Tom Keith-Roach, head of AstraZeneca's respiratory, inflammation and autoimmune business, said the results were good news for the sickest patients, who currently rely on oral steroids that can cause weight gain, mood changes and other side effects.

Data from the latest trial, along with results from two earlier studies, were included in regulatory submissions for benralizumab in various countries, including the United States, where an approval decision is due in the fourth quarter.

The picture was less favorable for Bydureon, where a separate clinical trial showed that while the injectable drug did not raise heart dangers, it failed to demonstrate a statistically significant reduction in cardiovascular risks.

Consensus industry analyst forecasts point to annual benralizumab sales of $915 million in 2023, while Bydureon is expected to sell $854 million, according to data compiled by Thomson Reuters.

In addition to competition from GSK and Teva, benralizumab also faces a potentially serious challenge from Sanofi and Regeneron, whose drug dupilumab is being tested for severe asthma after winning a green light in eczema.

Benralizumab works by directly killing off inflammatory cells found in the lungs called eosinophils and, unlike the two existing drugs, it is given only every eight weeks rather than monthly.

"There are around 2 million severe uncontrolled asthmatics worldwide in our top 12 markets and I certainly think based on this profile we would expect to have a really competitive share of that market," Keith-Roach said.

(Editing by Susan Thomas)

KISUMU, Kenya President Donald Trump's dramatic expansion of a policy blocking U.S. aid to organizations offering abortion services will have one sure result, say medical workers in this city: more abortions.

Cigarette filters, introduced decades ago to reduce the amount of tar smokers inhale, also alter other properties of smoke and smoking in a way that raises the risk of lung cancer, researchers say.

FRANKFURT Germany's highest court ruled on Tuesday that a father could have his child vaccinated according to a schedule recommended by authorities even though the mother of the girl is opposed.

See the rest here:
AstraZeneca asthma shot hits goal but diabetes drug lags rival - Reuters

Please enable Javascript to watch this video

Los Angeles Police officials are looking for a missing Studio City teen who has diabetes.

Angelique Faith Davis is seen in a photo released by LAPD officials on May 22, 2017.

Angelique Faith Davis, 13, was walking in the 3700 block of Fredonia Drive about 3:30 p.m. Sunday when she was last seen.

She has Type 1 diabetes and requires medication, officials said. She apparently is also depressed.

In an email, a woman describing herself asAngelique's mother said police used a helicopter and bloodhounds to search for her daughter to no avail.

Angelique is described as being 5 feet 7 inches tall and weighs about 128 pounds. She has brown hair, browneyes and freckles.

She was last seen wearing a purple blouse, blue shorts, white shoes and a black backpack.

Anyone with information about Angelique can call LAPD officials at 818 754-8410 or 818 754-8429.

34.139560 -118.387099

Continued here:
LAPD Officials Look for Missing Studio City Teen With Diabetes - KTLA